kwic
higher
higher
right
off
ON
207
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for higher out of >500 occurrences
487192 occurrences (No.29 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to higher]
487192 occurrences (No.29 in the rank) during 5 years in the PubMed. [cache]
| 207) There is no evidence that low-body-weight patients are at increased risk of cardiotoxicity with SC trastuzumab, although this may be confounded by the higher rate of cardiovascular comorbidities in overweight patients. |
| PMID:33799233 DOI:10.1016/j.breast.2021.03.003 |
| 2021 Breast (Edinburgh, Scotland) |
| * Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. |
| - Trastuzumab, a key treatment for HER2-positive breast cancer, is available in weight-based IV and fixed-dose (600 mg) SC formulations. While the Phase 3 HannaH trial indicated non-inferiority of the SC formulation, there is some concern that the target plasma concentration may not be reached in overweight/obese patients whereas low-body-weight patients may be at risk of toxicity. This scoping review evaluated whether overweight/obese patients are at risk of below-target exposure with fixed-dose SC trastuzumab, whether low-body-weight patients are at risk of increased toxicity, especially cardiotoxicity, and whether IV and SC trastuzumab are equivalent in terms of treatment-emergent adverse events (TEAEs) (e.g. infections). Thirty-seven publications that met the eligibility criteria were included. Body weight is not an important determinant of exposure to trastuzumab at steady state (i.e. pre-dose cycle 8); however, real-world evidence suggests that the target concentration (20 μg/mL) may not be reached with the first SC dose in overweight/obese patients. There is no evidence that low-body-weight patients are at increased risk of cardiotoxicity with SC trastuzumab, although this may be confounded by the higher rate of cardiovascular comorbidities in overweight patients. In Phase 3 trials, SC trastuzumab was associated with higher rates of ISRs, ADAs and SAEs, the latter often requiring hospitalization and occurring during adjuvant treatment when patients are not burdened by chemotherapy. The route of administration of trastuzumab (IV vs SC) in different treatment settings should be discussed with the patient, taking into account the risks and benefits associated with each route. |
[
right
kwic]
(1)37  than |
(14)5 mortality |
(27)2 activation |
(40)2 or |
| (2)33 in |
(15)4 concentrations |
(28)2 anti-E |
(41)2 percentage |
| (3)28 levels |
(16)4 proportion |
(29)2 at |
(42)2 performing |
| (4)27 risk |
(17)4 rate |
(30)2 auditory-perceptual |
(43)2 potency |
| (5)11 rates |
(18)4 regions |
(31)2 cognitive |
(44)2 risk, |
| (6)10 among |
(19)3 consumption |
(32)2 compared |
(45)2 scores |
| (7)8 for |
(20)3 frequency |
(33)2 disease |
(46)2 selectivity |
| (8)8 prevalence |
(21)3 plasma |
(34)2 doses |
(47)2 social |
| (9)7 education |
(22)3 quality |
(35)2 endostatin |
(48)2 stimulation |
| (10)7 level |
(23)3 sensitivity |
(36)2 extent |
(49)2 to |
| (11)6 expression |
(24)3 strength |
(37)2 from |
(50)2 tumor |
| (12)5 and |
(25)2 F |
(38)2 glutamate-cysteine |
(51)2 weight |
| (13)5 incidence |
(26)2 NAFLD |
(39)2 odds |
add keyword
--- WordNet output for higher ---